Antiviral Treatments Eliminate the Adverse Impacts of High Baseline HBV Loads on the Survival of HBV-Related HCC Patients

References

• Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209–249. doi:10.3322/caac.21660
   PubMed Web of Science ®Google Scholar
• Vogel A, Cervantes A, Chau I, et al. Hepatocellular carcinoma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2019;30(5):871–873. doi:10.1093/annonc/mdy510
   PubMed Web of Science ®Google Scholar
• Finn RS, Qin S, Ikeda M, et al. Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma. N Engl J Med. 2020;382(20):1894–1905. doi:10.1056/NEJMoa1915745
   PubMed Web of Science ®Google Scholar
• Kudo M, Finn RS, Qin S, et al. Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial. Lancet. 2018;391(10126):1163–1173. doi:10.1016/S0140-6736(18)30207-1
   PubMed Web of Science ®Google Scholar
• Lara PN, Higdon R, Lim N, et al. Prospective evaluation of cancer clinical trial accrual patterns: identifying potential barriers to enrollment. J Clin Oncol. 2001;19(6):1728–1733. doi:10.1200/JCO.2001.19.6.1728
   PubMed Web of Science ®Google Scholar
• Scoggins JF, Ramsey SD. A national cancer clinical trials system for the 21st century: reinvigorating the NCI Cooperative Group Program. J Natl Cancer Inst. 2010;102(17):1371. doi:10.1093/jnci/djq291
   PubMedGoogle Scholar
• Filion M, Forget G, Brochu O, et al. Eligibility criteria in randomized Phase II and III adjuvant and neoadjuvant breast cancer trials: not a significant barrier to enrollment. Clin Trials. 2012;9(5):652–659. doi:10.1177/1740774512456453
   PubMed Web of Science ®Google Scholar
• Lemieux J, Goodwin PJ, Pritchard KI, et al. Identification of cancer care and protocol characteristics associated with recruitment in breast cancer clinical trials. J Clin Oncol. 2008;26(27):4458–4465. doi:10.1200/JCO.2007.15.3726
   PubMed Web of Science ®Google Scholar
• Akinyemiju T, Abera S, Ahmed M, et al. The burden of primary liver cancer and underlying etiologies from 1990 to 2015 at the global, regional, and national level: results from the global burden of disease study 2015. JAMA Oncol. 2017;3(12):1683–1691. doi:10.1001/jamaoncol.2017.3055
   PubMed Web of Science ®Google Scholar
• El-Khoueiry AB, Sangro B, Yau T, et al. Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, Phase 1/2 dose escalation and expansion trial. Lancet. 2017;389(10088):2492–2502. doi:10.1016/S0140-6736(17)31046-2
   PubMed Web of Science ®Google Scholar
• Zhu AX, Finn RS, Edeline J, et al. Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label Phase 2 trial. Lancet Oncol. 2018;19(7):940–952. doi:10.1016/S1470-2045(18)30351-6
   PubMed Web of Science ®Google Scholar
• Kim ES, Bernstein D, Hilsenbeck SG, et al. Modernizing Eligibility Criteria for Molecularly Driven Trials. J Clin Oncol. 2015;33(25):2815–2820. doi:10.1200/JCO.2015.62.1854
   PubMed Web of Science ®Google Scholar
• Ohkubo K, Kato Y, Ichikawa T, et al. Viral load is a significant prognostic factor for hepatitis B virus-associated hepatocellular carcinoma. Cancer. 2002;94(10):2663–2668. doi:10.1002/cncr.10557
   PubMed Web of Science ®Google Scholar
• Heimbach JK, Kulik LM, Finn RS, et al. AASLD guidelines for the treatment of hepatocellular carcinoma. Hepatology. 2018;67(1):358–380. doi:10.1002/hep.29086
   PubMed Web of Science ®Google Scholar
• Vogel A, Cervantes A, Chau I, et al. Hepatocellular carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2018;29:238–255. doi:10.1093/annonc/mdy308
   Web of Science ®Google Scholar
• Pinter M, Jain RK, Duda DG. The current landscape of immune checkpoint blockade in hepatocellular carcinoma: a review. JAMA Oncol. 2021;7(1):113–123. doi:10.1001/jamaoncol.2020.3381
   PubMed Web of Science ®Google Scholar
• Howerton MW, Gibbons MC, Baffi CR, et al. Provider roles in the recruitment of underrepresented populations to cancer clinical trials. Cancer. 2007;109(3):465–476. doi:10.1002/cncr.22436
   PubMed Web of Science ®Google Scholar
• Ding CY, Peng L, Lin YX, Yu LH, Wang DL, Kang DZ. Elevated lactate dehydrogenase level predicts postoperative pneumonia in patients with aneurysmal subarachnoid hemorrhage. World Neurosurg. 2019;129:e821–e30. doi:10.1016/j.wneu.2019.06.041
   PubMed Web of Science ®Google Scholar
• Zhou H, Huang Y, Qiu Z, et al. Impact of prior cancer history on the overall survival of patients newly diagnosed with cancer: a pan-cancer analysis of the SEER database. Int J Cancer. 2018;143(7):1569–1577. doi:10.1002/ijc.31543
   PubMed Web of Science ®Google Scholar
• Yang T, Lu JH, Zhai J, et al. High viral load is associated with poor overall and recurrence-free survival of hepatitis B virus-related hepatocellular carcinoma after curative resection: a prospective cohort study. Eur J Surg Oncol. 2012;38(8):683–691. doi:10.1016/j.ejso.2012.04.010
   PubMed Web of Science ®Google Scholar
• Yu SJ, Lee JH, Jang ES, et al. Hepatocellular carcinoma: high hepatitis B viral load and mortality in patients treated with transarterial chemoembolization. Radiology. 2013;267(2):638–647. doi:10.1148/radiol.13121498
   PubMed Web of Science ®Google Scholar
• Yang Y, Wen F, Li J, et al. A high baseline HBV load and antiviral therapy affect the survival of patients with advanced HBV-related HCC treated with sorafenib. Liver Int. 2015;35(9):2147–2154. doi:10.1111/liv.12805
   PubMed Web of Science ®Google Scholar
• Koyama T, Kondo S, Shimizu T, et al. Impact of hepatitis virus on the feasibility and efficacy of anticancer agents in patients with hepatocellular carcinoma in phase I clinical trials. Front Oncol. 2019;9:301. doi:10.3389/fonc.2019.00301
   PubMed Web of Science ®Google Scholar
• Ge Z, Ma J, Qiao B, Wang Y, Zhang H, Gou W. Impact of tenofovir antiviral treatment on survival of chronic hepatitis B related hepatocellular carcinoma after hepatectomy in Chinese individuals from Qingdao municipality. Medicine (Baltimore). 2020;99(32):e21454. doi:10.1097/MD.0000000000021454
   PubMed Web of Science ®Google Scholar
• Xu L, Gao H, Huang J, et al. Antiviral therapy in the improvement of survival of patients with hepatitis B virus-related hepatocellular carcinoma treated with sorafenib. J Gastroenterol Hepatol. 2015;30(6):1032–1039. doi:10.1111/jgh.12910
   PubMed Web of Science ®Google Scholar
• Galle PR, Kudo M, Llovet JM, et al. Ramucirumab in patients with previously treated advanced hepatocellular carcinoma: impact of liver disease aetiology. Liver Int. 2021;41(11):2759–2767. doi:10.1111/liv.14994
   PubMed Web of Science ®Google Scholar
• Xu X, Huang P, Tian H, et al. Role of lamivudine with transarterial chemoembolization in the survival of patients with hepatocellular carcinoma. J Gastroenterol Hepatol. 2014;29(6):1273–1278. doi:10.1111/jgh.12554
   PubMed Web of Science ®Google Scholar
• Liu S, Lai J, Lyu N, et al. Effects of antiviral therapy on HBV reactivation and survival in hepatocellular carcinoma patients undergoing hepatic artery infusion chemotherapy. Front Oncol. 2020;10:582504. doi:10.3389/fonc.2020.582504
   PubMed Web of Science ®Google Scholar
• Zhong JH. Nucleos(t)ide analogue therapy for HBV-related HCC after hepatic resection: clinical benefits and unanswered questions. Tumour Biol. 2014;35(12):12779–12784. doi:10.1007/s13277-014-2881-1
   PubMedGoogle Scholar